UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001937
Receipt number R000002357
Scientific Title Randomized parallel controlled trial of "on demand" therapy versus continuous therapy of omepral 20mg in effectiveness and safety for the patients {Los Angeles classification grade M (LA M) or more)} diagnosed as the gastroesophageal reflux disease.
Date of disclosure of the study information 2009/05/02
Last modified on 2013/07/08 09:15:17

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomized parallel controlled trial of "on demand" therapy versus continuous therapy of omepral 20mg in effectiveness and safety for the patients {Los Angeles classification grade M (LA M) or more)} diagnosed as the gastroesophageal reflux disease.

Acronym

Randomized parallel controlled trial of refiux esophagitis

Scientific Title

Randomized parallel controlled trial of "on demand" therapy versus continuous therapy of omepral 20mg in effectiveness and safety for the patients {Los Angeles classification grade M (LA M) or more)} diagnosed as the gastroesophageal reflux disease.

Scientific Title:Acronym

Randomized parallel controlled trial of refiux esophagitis

Region

Japan


Condition

Condition

Gastroesophageal reflux disease (LA gradeM or more)

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Endoscopy examination is done after 8-weeks of the initial treatment for reflux esophagitis. Patients whose endoscopic diagnosis was LA M or more are included as tested subjects. The aim of the study is to examine whether "on demand" therapy that means to take the medicine only when symptoms occur or continuous therapy of omepral 20mg for 24 weeks for tested subjects is more effective or safer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Amount of change of GOS score between before and after treatment
Amount of change of QULRAS-J score between before and after treatment

Key secondary outcomes

Examination according to symptoms
Evaluation of safety


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is considered as a block.

Blocking

YES

Concealment

No need to know


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

"on demand" therapy of omepral 20mg for 24 weeks

Interventions/Control_2

continuous therapy of omepral 20mg for 24 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Patients had been classified into grade LA M, A, B, C, and D by endoscopy before initial treatment and whose endoscopic diagnosis was LA M and more after 8-weeks initial treatment.
2) Patients from who written informed consent was obtained.

Key exclusion criteria

1) Patients who suffer from cancer.
2) Patients who suffer from serious liver disease, kidney disease, heart disease, or Haematological disorder
3) Patients who had the past of irritability for omeprazole
4) Pregnant women and patienst while suckling, and patients who have been hoping for pregnancy for the trial period.
5) Patients who participated in other clinical trials which are thought to influence to the result of this trial within one month before the start of the trial.
6) Patients who refuse endoscopic examination.
7) Patients who suffer from gastric ulcers and/or duodenal ulcers
8) Patients who are judged inappropriate for the clinical trial by doctors.

Target sample size

200


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Akihito Nagahara

Organization

Juntendo University School of Medicine

Division name

Gastroenterology

Zip code


Address

2-1-1 Hongo bunkyo-ku tokyo Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Akihito Nagahara

Organization

Juntendo University School of Medicine

Division name

Gastroenterology

Zip code


Address


TEL


Homepage URL


Email



Sponsor or person

Institute

Department of Gastroenterology Juntendo University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2009 Year 05 Month 02 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2009 Year 04 Month 01 Day

Date of IRB


Anticipated trial start date

2009 Year 05 Month 01 Day

Last follow-up date

2012 Year 12 Month 31 Day

Date of closure to data entry

2012 Year 12 Month 31 Day

Date trial data considered complete

2013 Year 05 Month 31 Day

Date analysis concluded

2013 Year 09 Month 30 Day


Other

Other related information



Management information

Registered date

2009 Year 05 Month 02 Day

Last modified on

2013 Year 07 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002357


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name